ctDNA-based molecular residual disease and survival in resectable colorectal cancer
Nakamura, et al. Nature Medicine 2024
Read More
Signatera
Resources related to Signatera residual disease testing from a simple drop of blood.
-
-
Target, Track, Treat: Optimizing GI Cancer Management with Molecular Residual Disease Testing
Watch Video
-
Meet Anj, Breast Cancer Survivor and Signatera Patient
Watch Video
-
Post-Treatment H&N Cancer Surveillance with ctDNA
Read More
-
Tumor-informed ctDNA assay to predict recurrence in locally advanced squamous-cell carcinoma of the head and neck (SCCHN)
Honoré N, et al. ESMO 2025
Read More
-
Correlative Analysis of Tumor-Informed Circulating Tumor DNA (ctDNA) and the Survival Outcomes of Patients with Pancreatic Adenocarcinoma
Zhang Y, et al. Biomedicines. 2025
Read More
-
Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Ca
Abdelrahim M, et al. JCO Preci Oncol. 2025
Read More
-
Circulating Tumor DNA Detects Minimal Residual Disease in Patients with Locally Advanced Rectal Cancer After Total Neoadjuvant Therapy
Kim J, et al. Cancers 2025
Read More
-
Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcin
Zaanan et al. Nat Commun, 2025
Read More
-
Anal Cancer Sales Aid
Read More
-
Biliary Cancer Sales Aid
Read More
-
Meet Holly, Clear Cell Ovarian Cancer Survivor and Signatera Patient
Clear cell ovarian cancer can return—even years after treatment. #Signatera, Natera’s personalized MRD (ctDNA) test, looks for tiny traces of tumor DNA between scans and may detect molecular signs mon
Watch Video
-
Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA
Powles et al, ASCO 2025
Read More
-
Longitudinal ctDNA monitoring for post-surgical molecular residual disease in patients with stage I-IIIb melanoma
Ansstas et al, ASCO 2025
Read More
-
Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 t
Mukhtar et al, ASCO 2025
Read More
-
Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC)
Razavi et al, ASCO 2025
Read More
-
Circulating tumor (ct)DNA monitoring of ER+/HER2- high-risk breast cancer during adjuvant endocrine therapy
Pusztai et al, ASCO 2025
Read More
-
Zaanan 2025 Nature Communications
Read More
-
Abdelrahim 2025 ctDNA and HCC
Read More
-
Nasca et al. TRINITY Study Protocol - 2025 BMC Cancer
Read More
-
Loading More...
